Kornimate/medical-research-clean huggingface dataset:
relaxation training for people with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: people with chronic obstructive pulmonary disease (copd) suffer from dyspnoea, which may be exacerbated by psychological outcomes including anxiety and depression. previous studies suggest that relaxation techniques may have positive effects on pulmonary rehabilitation. the main aim of this study is to explore both the respiratory and psychological impact of a quick, one-session, relaxation training for people with chronic obstructive pulmonary disease (copd).


Eligibility criteria:
inclusion criteria: * written informed consent; * chronic obstructive pulmonary disease (copd) diagnosis confirmed by a specialized physician; * basal fev1/fvc \<70%, using the standards established by global initiative for chronic obstructive lung disease (gold); * modified british medical research council questionnaire (mmrc) ≥ 2; * copd assessment test (cat) ≥ 10. exclusion criteria: * pregnancy; * psychiatric disturbances; * oncological diseases; * comorbid states that determine an immunosuppressive condition.

Keywords: chronic obstructive pulmonary disease (copd) relaxation technique anxiety
effect of oral adenosine-triphosphate (atp) on human muscle performance

Conditions: Healthy Subjects

Summary: adenosine-triphosphate (atp) serves as the sole energy source for muscle contraction. therefore human performance of brief maximal exercise is limited, in part, by the availability of atp to the contracting muscle. because muscle atp storage is small (enough to sustain maximal exercise for less than 1 second), factors that enhance either storage or resynthesis of atp may have a positive impact on repeated muscle contractions. the current study will test the hypothesis that increasing atp availability to muscle via oral supplementation will improve performance of repeated high intensity exercise as measured by a) work performed in each of the three 50 contraction fatigue tests, b) sum of total work performed, and c) percentage decrement in total work from the first to third third 50 contraction test.

to date we have studied 10 subjects who have followed through with all 3 of the original interventions (placebo, 250 mg peakatp/d and 400 mg peakatp/d). currently we have received approval and are expanding the study with 5 additional subjects who will receive the placebo, 400 mg peakatp/d and the 400 mg pealatp/d plus proprietary blend interventions.

Eligibility criteria:
inclusion criteria: * no major medical conditions; * able to perform fatigue testing procedures; * not currently taking prescription medications; * not currently taking dietary supplements (a daily multi-vitamin not exceeding rda is permitted) exclusion criteria: * major medical condition affecting metabolism or general function; * not able to perform fatigue testing; * taking prescription medications; * taking a dietary supplement other than a multi-vitamin not exceeding rda

Keywords: supplemental atp muscle work performed muscle fatigue
safety assessment of lactobacillus salivarius cect5713 in 6 months old children

Conditions: Infection

Summary: the aim of the trial is to evaluate safety of a follow on formula supplemented with lactobacillus salivarius cect5713. a randomized double blind placebo controlled trial was carried out. eighty six months old children were recruited by the department of pediatrics of hospital univeristario san cecilio. children were divided in two groups that consumed a follow on formula supplemented or not with the probiotic strain during 6 months. fecal samples were obtained at the recruitment, at 3 months and at the end of the trial. in addition revision by the pediatrician was performed once a month and possible adverse effects were recorded both by the pediatrician and by parents.


Eligibility criteria:
inclusion criteria: * healthy six months old children exclusion criteria: * lactose intolerance * cow's milk protein allergy * serious metabolic diseases * antibiotic treatment * serious gastrointestinal diseases

Keywords: probiotics safety fecal microbiota infections
clinical study of lpi on different sites of iris

Conditions: Glaucoma

Summary: glaucoma is the second cause of blindness worldwide. laser peripheral iridoplasty (lpi) is a simple and effective treatment for angle closure glaucoma. lpi can widen or reopen an existing angle close or angle adhesion in order to reduce the risk of attack of the angle closure glaucoma. however, there are very little research on the laser site, laser wavelengths, laser energy and laser spot intervals. the purpose of this study is to determine the optimum laser site of lpi.

glaucoma is the second cause of blindness worldwide. laser peripheral iridoplasty (lpi) is a simple and effective treatment for angle closure glaucoma. lpi can widen or reopen an existing angle close or angle adhesion in order to reduce the risk of attack of the angle closure glaucoma. however, there are very little research on the laser site, laser wavelengths, laser energy and laser spot intervals. the purpose of this study is to determine the optimum laser site of lpi. before and 7days, 1 month, 3 months after lpi, the structure of anterior chamber, including angle anterior chamber depth(acd), angle of anterior chamber (aa), anterior chamber angle opening distance 750(aod750) are measured with ultrasound biomicroscopy. before and 7days, 1 month, 3 months after lpi, the outflow resistance of aqueous humor are evaluated with c value. before and 1hour, 1days, 3day, 7days, 1 month, 3 months after lpi, intraocular pressure are measured with goldmann tonometry. before and 3 months after lpi, retinal nerve layer thickness and the optic disc cup disc ratio are measure with optical coherence tomography.

Eligibility criteria:
inclusion criteria: * patients with primary angle closure suspect (pacs), primary angle closure (pac) or primary angle closure glaucoma (pacg). * pacs is diagnosed in eyes with an occludable angle but no other abnormality. * pac is diagnosed in eyes with an occludable angle, normal optic discs and visual fields and any of the following: raised iop (\>19 mm hg), pas, pigment smearing in the superior angle, or sequelae of acute angle closure (iris whirling or glaucomatous fleck). * pacg is diagnosed in eyes with an occludable angle and glaucomatous optic neuropathy. evidence of glaucomatous optic neuropathy is defined as a cup: disc ratio (cdr) of \>0.7 or \>0.2 cdr asymmetry. * an occludable angle is defined as one in which three quarters of the posterior pigmented trabecular meshwork is not visible on viewing with a goldmann two mirror lens in the primary position of gaze without indentation. exclusion criteria: * patients with previous ocular surgery, and those with secondary angle closure, such as lens intumescence or subluxation, iris neovascularisation and a history of uveitis. * patients who have systemic contraindications to medical therapy (including renal impairment, sulfur allergy, asthma and heart failure), pre-existing corneal opacities obstructing laser access to more than one quadrant of the peripheral iris and single-eyed patients are also excluded.

Keywords: laser peripheral iridoplasty treatment
feasibility trial of valentx endo bypass system

Conditions: Obesity

Summary: the purpose of the study is to provide initial clinical data to support the feasibility of use of the valentx endo bypass system in enhancing weight loss and co-morbidity resolution in morbidly obese patients.

this is a single center open label feasibility study to evaluate the safety, efficacy and performance of the valentx endo bypass system.

Eligibility criteria:
inclusion criteria: * male or female between 18 and 55 years of age * \>=35 kg/m2 and \<= 50 kg/m2, with or without comorbid conditions(s). * documented failure with non-surgical weight loss methods * willing to comply with study procedures and visit schedule * willing and able to provide informed consent exclusion criteria: * pregnancy or intention of becoming pregnant within the study duration. * endoscopic lesions such as important hiatal hernia, gastric or duodenal ulcer, atresias or stenosis, polyps of the stomach. * subject with potential upper gastrointestinal bleeding such as esophageal or gastric varices, mallory-weis syndrome or congenital or acquired intestinal telangiectasia. * past history of esophageal or gastric/gi surgery, obstruction, adhesive peritonitis, or large hiatal hernia (\> 3 cm). * ibs, unexplained intermittent vomiting, severe abdominal pain or chronic constipation within 60 days of study day 1 * unexplained anaemia, pancreatitis, portal hypertension, esophagitis or barrett's esophagus, known gallstones or anomalies of the gi tract * any bodily infections within 30 days of study day 1. * prolonged steroid use * hep c or hiv positive * known allergies to any of the device materials * use of weight loss medication or an investigational drug or device within 2 months prior to enrolment and throughout the study period. * recent or ongoing cancer, history of severe renal, hepatic, cardiovascular or pulmonary disease or transplants * inability to tolerate anti-inflammatory medications * evidence of psychiatric problems or dietary habits that would contraindicate study treatment; * active drug or alcohol addiction within 12 months of enrolment and throughout the study duration. * prior history of inflammatory diseases of the gi tract, (e.g., esophagitis, varices, gastric or duodenal ulceration, or crohn's disease; congenital or acquired gi anomalies, e.g., bowel strictures) * ongoing treatment with anticoagulants, steroids, aspirin, nsaids, or other gastric irritants within 1 month prior to enrollment and throughout the study period. * participation in previous (within 60 days of study day 1) or ongoing clinical trial or current or past usage (within 60 days of study day 1) of investigation drug or device.

Keywords: obesity
comprehensive nutritional geriatric assessments in identifying malnutrition in older cancer participants

Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this trial studies how well comprehensive nutritional geriatric assessments work in identifying malnutrition in older cancer participants. comprehensive nutritional geriatric assessments may help doctors learn about ways to check for malnutrition (loss of weight/appetite that may result in health problems) that is due to cancer or cancer treatment.

primary objectives: i. to evaluate whether nutritional status, as determined by each of 4 screening tools (mini nutritional assessment \[mna\], weight loss, body mass index \[bmi\], and lean muscle mass), correlates with 6-month and 12-month mortality in older cancer patients after geriatric assessment, after adjusting for covariates. ii. to evaluate whether nutritional status, as determined by each of by 4 screening tools (mna, weight loss, bmi, and lean muscle mass) correlates with 6-month and 12-month unplanned hospitalization in older cancer patients who undergo geriatric assessment, after adjusting for covariates. iii. to evaluate whether nutritional status, as determined by each of 4 screening tools (mna, weight loss, bmi, and lean muscle mass) correlates with 6-month and 12-month hospital readmissions in older cancer patients who undergo geriatric assessment, after adjusting for covariates. outline: participants undergo nutritional geriatric assessment over 15 minutes in person or on the phone every 3 months for 12 months.

Eligibility criteria:
inclusion criteria: * with hematologic and solid tumor cancers. * undergo a comprehensive geriatric assessment by a geriatrician. exclusion criteria: * unable or unwilling to sign consent form. * life expectancy under 6 months.
effectiveness of chinese covid-19 vaccines in latin america and the caribbean

Conditions: COVID-19

Summary: this multi-country study seeks to collect real-world evidence (rwe), from latin american and caribbean countries, on the effectiveness of china-made covid-19 vaccines in different populations, against different clinical outcomes, and when administered in different schedules.

this multi-country study seeks to collect rwe, from latin american and caribbean countries, on the effectiveness of china-made covid-19 vaccines in different populations, against different clinical outcomes and when administered in different schedules. the vaccines of interest are the following: * 'sinovac-coronavac' (sinovac biotech ltd., beijing, china), * 'bibp covid-19 vaccine' ('covilo'; 'bibp-corv') (sinopharm, beijing institute of biological products, china), * 'convidecia' ('ad5-ncov') (cansino biologics, tianjin, china).

Eligibility criteria:
inclusion criteria patients need to fulfill all the following criteria to be eligible for the study: * being 18 years old or older * ever eligible for vaccination2 with any of the chinese covid-19 vaccines provided in their country as per national/regional immunization recommendations prior to hospital admission * er consultation or hospitalization due to sari * willing and able to provide informed consent (or by a legally accepted representative if the patient is not able to provide a signature by him/herself) exclusion criteria patients that fulfill one or more of the following criteria will not be eligible for the study: * patients vaccinated against covid-19 but not with the vaccines of interest * patients admitted or hospitalized for other condition than sari * patients to whom it is not possible to perform a diagnostic test (antigen or pcr) for sars-cov-2
prevalence of the metabolic syndrome in spr taking antipsychotics

Conditions: Metabolic Syndrome; Schizophrenia

Summary: the purpose of this study is to assess the cross-sectional prevalence of the metabolic syndrome in patients with schizophrenia taking antipsychotics.

schizophrenic patients taking any kind of antipsychotics for at least 1 year at the seoul national hospital will be participated in this study. we are planning to enroll approximately 1000 patients with schizophrenia. for each subject * abdominal circumference * body mass index * lipid profile : tg, hdl-chlo, total chol * systolic/diastolic blood pressure * fasting blood glucose will be measured. we will calculate the rates of patients who meet the criteria for the metabolic syndrome. 1. abdominal obesity : absolute criteria 2. 2 or more of followings 1. triglyceride ≥ 150mg/dl or ongoing treatment 2. hdl-cholesterol \< 40mg/dl (men) hdl-cholesterol \< 50mg/dl (female) or ongoing treatment 3. hypertension 130mmhg ≥ systolic 85mmhg ≥ diastolic or ongoing treatment 4. fbs ≥ 100mg/dl or previous diagnosis of type ii dm

Eligibility criteria:
inclusion criteria: * patients taking a same antipsychotics at least more than one year * schizophrenia or schizoaffective disorder exclusion criteria: * none

Keywords: schizophrenia antipsychotics metabolic syndrome prevalence
follow-up of migraine patients on eptinezumab

Conditions: Migraine

Summary: the october 2022 transparency commission considers that vyepti (eptinezumab) is a treatment option for patients suffering from severe migraine with at least 8 migraine days per month, who have failed at least two prophylactic treatments and have no cardiovascular impairment. since the beginning of 2023, eptinezumab has been available in france as an inpatient treatment prescribed by a migraine neurologist in a growing number of centres. the saint-denis hospital and the nîmes university hospital are among the first centres to have started. the investigators from these 2 centres have therefore decided to pool their data to provide the first french feedback on its effectiveness.


Eligibility criteria:
inclusion criteria: * adult patients suffering from severe migraine with at least 8 migraine days per month * patients who have failed at least 2 disease-modifying treatments, * patients treated with quarterly infusions of eptinezumab since march 2023 in a day hospital at saint-denis hospital and nîmes university hospital. exclusion criteria: * patient refusing to participate
mechanism of ketogenic diet-induced hypercholesterolemia

Conditions: Hypercholesterolemia and Hyperlipidemia

Summary: very-low carbohydrate ketogenic diets can dramatically increase blood cholesterol levels, particularly in normal-weight people, for reasons that are not well understood. this study will enroll normal-weight adults, will identify "responders" who develop high cholesterol on a ketogenic diet, and will measure rates of production and removal of certain types of cholesterol-carrying particles called lipoproteins in responders. the results will clarify the mechanism by which a ketogenic diet can cause high cholesterol in certain susceptible people.

this study will evaluate the mechanism of ketogenic diet-induced hypercholesterolemia in susceptible normal-weight adults. the first stage of screening will identify eligible young adults who are normal-weight and at low cardiovascular risk. the second stage of screening will identify "responders" who demonstrate susceptibility to ketogenic diet-induced hypercholesterolemia by displaying an increase in ldl-cholesterol concentration after a 3-week screening ketogenic diet. responders will be eligible to complete a randomized crossover clinical study at washington university school of medicine in st. louis, mo. the randomized crossover study will involve isotope tracer studies of lipoprotein and cholesterol kinetics after two separate 4-week dietary interventions \[ketogenic diet and control diet\], conducted in random order with a 4-week washout period between interventions. all food will be provided to the participants as packed-out meals. certain outcomes will use data from the screening process, comparing screen successes and screen failures to evaluate factors that could influence susceptibility to ketogenic diet-induced hypercholesterolemia.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 and \< 40 years 2. bmi ≥ 18.5 and \< 25.0 kg/m2 3. baseline serum ldl-c \< 150 mg/dl (\< 3.9 mmol/l) 4. baseline serum tg \< 100 mg/dl (\< 1.1 mmol/l) 5. hba1c ≤ 5.6%. exclusion criteria: 1. personal or family history of familial hypercholesterolemia 2. current use of lipid-lowering drugs 3. currently on a ketogenic diet and unwilling to change diet 4. current tobacco use 5. hypertension 6. prediabetes or diabetes 7. elevated lp(a) \> 6.5% of apob-containing lipoproteins at baseline 8. oral contraceptive use 9. contraindication to heparin 10. known atherosclerotic cardiovascular disease 11. unwilling to abstain from alcohol

Keywords: ldl-cholesterol cholesterol ketogenic diet lipoprotein kinetics
small-volume, patient-specific, balanced hypertonic fluid protocol validation

Conditions: Cerebral Edema; Saline Solution, Hypertonic

Summary: many patients with traumatic brain injuries (including strokes, blood clots, or other brain injuries) are given concentrated salt water solutions (hypertonic saline) in order to treat brain swelling (cerebral edema). current therapies consist of a mixture of sodium and chloride, which can lead to high levels of serum chloride and increased total body water. high levels of chloride can cause acidosis, which can cause the body to function sub-optimally. therefore, the investigators are proposing to use two concentrated solutions in these patients at the same time that will allow for a lower total volume of solution administration and reduce the rise in chloride to prevent acidosis. the main outcome will therefore be the patients sodium level, chloride level and serum ph.


Eligibility criteria:
inclusion criteria: * able to consent * 18 years or older * english speaking * clinical indication (intracranial hypertension from cerebral edema) for hypertonic fluid administration exclusion criteria: * fails to consent * \< 18 years old * hypertonic therapy not indicated
pharmacological interaction between pindolol and mdma (3,4-methylenedioxymethamphetamine)

Conditions: Mood Disorder; Substance-Related Disorders; Amphetamine-Related Disorders

Summary: mdma (3,4-methylenedioxymethamphetamine, "ecstasy") produces tachycardia, hypertension, hyperthermia, and other acute adverse effects. ecstasy use has also been associated with rare cardio- and cerebrovascular complications. the role of beta-blockers in the treatment of cardiovascular and adverse effects of mdma is unknown.

we investigated the interactive effects of the beta-blocker pindolol (20 mg) with mdma (1.6 mg/kg) on heart rate, blood pressure, body temperature, and adverse effects in a double-blind placebo-controlled study in 16 healthy subjects.

Eligibility criteria:
inclusion criteria: * sufficient understanding of the german language * subjects understand the procedures and the risks associated with the study * participants must be willing to adhere to the protocol and sign the consent form * participants must be willing to refrain from taking illicit psychoactive substances during the study. * participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids after midnight of the evening before the study session. * participants must be willing not to drive a traffic vehicle in the evening of the study day. * body mass index: 18-25 kg/m2 exclusion criteria: * chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ecg. in particular: hypertension (\>140/90 mmhg). personal or first-grade history of seizures. cardiac or neurological disorder. * current or previous psychotic or affective disorder * psychotic or affective disorder in first-degree relatives * prior illicit drug use (except thc-containing products) more than 5 times or any time within the previous 2 months. * participation in another clinical trial (currently or within the last 30 days) * use of medications that are contraindicated or otherwise interfere with the effects of the study medications.

Keywords: mdma beta adrenergic ecstasy
trial for treatment of adult patients with standard risk acute lymphoblastic leukemia with chemotherapy and rituximab

Conditions: Adult Acute Lymphocytic Leukemia

Summary: the study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy in combination with rituximab in cd20 positive standard risk patients. thereafter patients receive additional consolidation and reinduction cycles combined with rituximab. in parallel minimal residual disease is evaluated. after six months and one year the decision on intensification or discontinuation of therapy is made based on results of mrd evaluation


Eligibility criteria:
inclusion criteria: * b-precursor all (common / pre b-all) * standard risk * cd20 expression \>20% * ph/bcr-abl negative * age 15-65 years (55-65 if biologically younger) * written informed consent exclusion criteria: * severe complications due to leukemia or secondary illnesses * late relapse of childhood all * cytostatic pretreatment * pregnancy * severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent * known severe allergy to foreign proteins

Keywords: all treatment de novo minimal residual disease rituximab adult
early feasibility study to assess safety and device performance of acousticare™

Conditions: Heart Failure，Congestive

Summary: acousticaretm is a non-invasive clinical tool used for the detection of intracardiac pressures using heart sounds in patients with heart failure.


Eligibility criteria:
inclusion criteria: 1. male or female subjects between the ages of 18 - 80 years 2. willing and able to sign informed consent form 3. normal subjects without a history of heart disease who are recruited from the surrounding community 4. subjects with heart failure undergoing treatment in a hospital setting exclusion criteria: 1. hemodynamic instability (systolic bp\>180 or \ 90 and \<60) 2. acute coronary syndrome 3. prior heart transplant recipients 4. subjects who are pacemaker dependent 5. severe obesity (body mass index \> 40 kg/m2) 6. subjects who are pregnant